Login to Your Account

Iniparib Misses in Breast Cancer; Sanofi Still in Genzyme Talks

By Jennifer Boggs

Monday, January 31, 2011
One of the drugs Sanofi-Aventis SA had hoped would shore up its product pipeline ahead of patent expirations may be out of the picture, but that setback could have little impact in ongoing acquisition negotiations for Genzyme Corp.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription